PIPAC practice in Spain: a national benchmark defining evidence-driven restraint and a three-phase hypothesis of PIPAC implementation
European Journal of Surgical Oncology · 2027-01 · 53 (1) · 112176
DOI: 10.1016/j.ejso.2026.112176 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2027-01. Verfasst von Juan José Segura-Sampedro und 6 weiteren Autor:innen. Beteiligte Einrichtung: General & Digestive Surgery Service, Hospital Universitario La Paz, IdiPAZ, Madrid, 28046, Spain; School of Medicine, Universidad San Pablo-CEU, CEU …. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has expanded internationally, yet its role remains uncertain due to the lack of high-level evidence and heterogeneous clinical adoption. In this context, national benchmarking is relevant not only for technical standardization but also for governance and patient protection in predominantly palliative settings. METHODS: We conducted a national, cross-sectional, web-based survey (51 items) among 43 GECOP-affiliated centers (December 2025-March 2026). A total of 32 valid center-level responses were analyzed. Results were summarized descriptively. RESULTS: Most responding centers were tertiary-level hospitals (78.1%) and public institutions (87.5%), all with established HIPEC programs and extensive experience in peritoneal disease management (81.3% > 10 years). An active PIPAC program was reported by 11/32 centers (34.4%), while 21/32 (65.6%) were not currently performing PIPAC. Among the 14/21 non-adopting centers that provided a reason, the main barrier was insufficient or inconclusive evidence (9/14, 64.3%), followed by organizational and resource constraints and clinical or implementation-related concerns (both 5/14, 35.7%). Only 5/21 centers (23.8%) explicitly reported referral of selected patients to active centers. Among active centers, procedural aspects were highly standardized, including universal adoption of a two-trocar approach (100%), balloon trocars (100%), and systematic safety checklists (90.9%). However, substantial heterogeneity was observed in oncological management, including chemotherapy regimens, dosing strategies, and integration with systemic therapy. The most commonly used regimen was cisplatin-doxorubicin (81.8%), with additional use of oxaliplatin (45.5%), taxanes (18.2%), or mitomycin C (9.1%). Response assessment consistently included peritoneal biopsies and PRGS (100%), frequently combined with PCI (90.9%), but remained heterogeneous in sampling strategies and adjunctive methods. At least one severe complication (Clavien-Dindo ≥3) was reported by 3/11 active centers (27.3%), this represents a center-level report rather than a procedure-level complication rate. CONCLUSIONS: Within Spanish specialized peritoneal oncology units, PIPAC is implemented in a moderate proportion of centers with insufficient or inconclusive evidence being the most frequently reported barrier among centers providing a reason for non-adoption. Its current use is predominantly palliative, with gastric and colorectal cancer and peritoneal mesothelioma being the most frequently reported indications. It is characterized by marked heterogeneity in indications, treatment strategies, and response evaluation. This variability likely reflects the underlying evidence gap. Rather than discouraging its use, these findings support the need for structured development through prospective clinical trials, centralized data collection, and governance within experienced multidisciplinary teams. These findings allow us to propose a three-phase hypothesis of PIPAC implementation, characterized by initial standardization, subsequent diversification, and current uncertainty-driven practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General & Digestive Surgery Service, Hospital Universitario La Paz, IdiPAZ, Madrid, 28046, Spain; School of Medicine, Universidad San Pablo-CEU, CEU Universities, Madrid, 28660, Spain. Electronic address: segusamjj@hotm…
- GI Surgical Oncology Unit, MD Anderson Cancer Center Madrid-Hospiten, Madrid, Spain.
- Department of Surgical Oncology, IVOQA, Santa Elena Viamed University Hospital, Madrid, 28003, Spain.
- General and Digestive System Surgery, Hospital Universitario Nuestra Señora de la Candelaria, Spain.
- Peritoneal Surface Malignancies Unit, Department of Surgery, CHU Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
- Department of Surgery, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Zitieren
APA
Segura-Sampedro, J. J., Ortega-Pérez, G., Cortés-Guiral, D., Concepción-Martín, V., Bijelic, L., Pereira, F., & SEOQ/GECOP group (2027). PIPAC practice in Spain: a national benchmark defining evidence-driven restraint and a three-phase hypothesis of PIPAC implementation. European Journal of Surgical Oncology, 53(1), 112176. https://doi.org/10.1016/j.ejso.2026.112176
Vancouver
Segura-Sampedro JJ, Ortega-Pérez G, Cortés-Guiral D, Concepción-Martín V, Bijelic L, Pereira F, et al. PIPAC practice in Spain: a national benchmark defining evidence-driven restraint and a three-phase hypothesis of PIPAC implementation. European Journal of Surgical Oncology. 2027;53(1):112176. doi:10.1016/j.ejso.2026.112176
BibTeX
@article{SeguraSampedro2027,
author = {Segura-Sampedro, Juan José and Ortega-Pérez, Gloria and Cortés-Guiral, Delia and Concepción-Martín, Vanessa and Bijelic, Lana and Pereira, Fernando and SEOQ/GECOP group, SEOQ/GECOP group},
title = {PIPAC practice in Spain: a national benchmark defining evidence-driven restraint and a three-phase hypothesis of PIPAC implementation},
journal = {European Journal of Surgical Oncology},
year = {2027},
volume = {53},
number = {1},
pages = {112176},
doi = {10.1016/j.ejso.2026.112176}
}
EUVIMED